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Background: Kinase fusion has been detected in a variety of cancer types. Approximately 3% of
cancers are associated with different kinase fusions, including fibrolamellar hepatocellular
carcinoma (FLC). FLC is a rare type of liver cancer that predominantly occurs in teenage
population without any previous liver disease history. It is aggressive and currently surgical
resection remains the only effective therapeutics. DNAJB1-PRKACA fusion is detected in at
least 80% of FLC cases and is considered a potential oncogenic factor. However, the causality
between DNAJB1-PRKACA fusion and FLC is not yet established.
Methods: This study aims at investigating the function of DNAJB1-PRKACA fusion in FLC
oncogenesis using Drosophila and murine in vivo models. We used the Gal4/UAS system to
overexpress human DNAJB1-PRKACA fusion gene in Drosophila eyes and used genetic and
pharmaceutical inhibition of PKA activity to rescue the eye phenotype. We also used
CRISPR/Cas9 genome engineering to recreate the murine chromosomal deletion equivalent to
that found in FLC patients. gRNAs were designed to target murine DNAJB1 and PRKACA
introns and tested for their editing efficiency. Co-transfection of a pair of effective gRNAs
successfully generated a 360kb chromosomal deletion on chromosome 8 in murine hepatocytes.
Multiple single cell clones were isolated, first characterized for their in vitro proliferation
properties, and further inoculated subcutaneously in vivo to monitor their oncogenicity.
Results: Human DNAJB1-PRKACA fusion gene, when expressed in Drosophila eye progenitor
cells, induced proliferation and differentiation phenotypes, including decreased eye size and
abnormal eye shape. Both genetic and pharmaceutical inhibition of PKA activity rescued the fly
eye phenotype. Murine hepatocyte cell lines carrying endogenous DNAJB1-PRKACA fusion
gene have higher PKA activity like in FLC patients. These engineered hepatocytes formed
subcutaneous tumors at faster rate in vivo and significantly promoted ductular metaplasia tumors.
Conclusion: DNAJB1-PRKACA fusion gene expression alone is sufficient to perturb cell
growth and differentiation in different cellular contexts. In vivo modeling with engineered
murine hepatocytes recapitulates certain prominent aspects of FLC pathological features,
confirming its proposed role as a driver oncogene for FLC. Our Drosophila FLC model is ready
as a medium throughput platform for FLC therapeutic screens.

